Congenital dyserythropoietic anemia type II

Congenital dyserythropoietic anemia type II (CDA II), or hereditary erythroblastic multinuclearity with positive acidified serum lysis test (HEMPAS)[1] is a rare genetic anemia in humans characterized by hereditary erythroblastic multinuclearity with positive acidified serum lysis test.[2]

Congenital dyserythropoietic anemia type II
Specialty Hematology Edit this on Wikidata

Genetics

CDA type II is caused by mutations in the SEC23B gene. This gene provides instructions for making a protein that is involved in the transport of other proteins within cells. During the development of red blood cells, this protein may help ensure that proteins are transported to the areas where they are needed. Researchers are working to determine how mutations in the SEC23B gene lead to the signs and symptoms of CDA type II.[3]

Analyses of CDA II erythrocyte membranes showed that the band 3 glycoprotein is underglycosylated. An aberrant glycosylation pattern is seen in the polylactosamine carbohydrates which are normally attached to the band 3 and band 4.5 glycoproteins. The polylactosamines are, however, accumulated in the form of glycolipids. Therefore a genetic factor in CDA II appears to block the glycosylation of protein acceptors and shift these carbohydrates to the lipid acceptors. Structural analysis of CDA II band 3 carbohydrates identified truncated hybrid-type oligosaccharides and suggests that the Golgi glycosylation enzyme(s), alpha-mannosidase II or N-acetylglycosaminyltransferase II is defective in CDA II.[2]

Type OMIM Gene Locus
CDAN2 224100 SEC23B 20q11.2

Diagnosis

The anemia associated with CDA type II can range from mild to severe, and most affected individuals have jaundice, hepatosplenomegaly, and the formation of hard deposits in the gallbladder called bilirubin gallstones. This form of the disorder is usually diagnosed in adolescence or early adulthood. An abnormal buildup of iron typically occurs after age 20, leading to complications including heart disease, diabetes, and cirrhosis.[3]

Treatment

Treatment consists of frequent blood transfusions and chelation therapy. Potential cures include bone marrow transplantation and gene therapy.

See also

References

  1. ↑ Fukuda MN. "HEMPAS. Hereditary erythroblastic multinuclearity with positive acidified serum lysis test". Biochim Biophys Acta. 1455: 231–9. doi:10.1016/S0925-4439(99)00070-8. PMID 10571015.
  2. 1 2 Fukuda, Michiko N. (1993). "Congenital dyserythropoietic anaemia type II (HEMPAS) and its molecular basis". Baillière's Clinical Haematology. 6 (2): 493–511. doi:10.1016/S0950-3536(05)80156-8. PMID 8043936.
  3. 1 2 "CDA - Genetics Home Reference". Ghr.nlm.nih.gov. 2012-07-02. Retrieved 2012-07-09.

Further reading

  • McCann, Shaun R; Firth, R; Murray, Nuala; Temperley, I J (1980). "Congenital dyserythropoietic anaemia type II (HEMPAS): A family study". Journal of Clinical Pathology. 33 (12): 1197–201. doi:10.1136/jcp.33.12.1197. PMC 1146375. PMID 7451666.
  • Heimpel, Hermann; Anselstetter, Volker; Chrobak, Ladislav; Denecke, Jonas; Einsiedler, Beate; Gallmeier, Kerstin; Griesshammer, Antje; Marquardt, Thorsten; et al. (2003). "Congenital dyserythropoietic anemia type II: Epidemiology, clinical appearance, and prognosis based on long-term observation" (PDF). Blood. 102 (13): 4576–81. doi:10.1182/blood-2003-02-0613. PMID 12933587.
  • Congenital dyserythropoietic anemia at the US National Institutes of Health Home Genetic Reference
Classification
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.